Anatara Lifesciences Ltd (ASX:ANR)
Australia · Delayed Price · Currency is AUD 0.0100
0.00 (0.00%)
Sep 1, 2026, 12:31 PM AEST
Anatara Lifesciences Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.47 | 0.1 | 0.98 | 0.35 | 1.12 |
Short-Term Investments | - | - | - | 0.05 | 0.05 |
Cash & Short-Term Investments | 0.47 | 0.1 | 0.98 | 0.4 | 1.17 |
Cash Growth | 364.62% | -89.68% | 144.80% | -65.72% | -65.90% |
Accounts Receivable | 0.33 | - | - | - | - |
Other Receivables | - | 1.03 | 0.67 | 1 | 0.51 |
Receivables | 0.33 | 1.03 | 0.67 | 1 | 0.51 |
Other Current Assets | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 |
Total Current Assets | 0.82 | 1.15 | 1.67 | 1.42 | 1.7 |
Property, Plant & Equipment | - | 0 | 0 | 0 | 0.07 |
Total Assets | 0.82 | 1.15 | 1.67 | 1.42 | 1.77 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.1 | 0.17 | 0.25 | 0.44 | 0.15 |
Accrued Expenses | 0.01 | 0.02 | 0.03 | 0.02 | 0.15 |
Short-Term Debt | - | 0.41 | - | - | - |
Current Portion of Leases | - | - | - | - | 0.02 |
Other Current Liabilities | - | 0.01 | 0.02 | 0.04 | 0.03 |
Total Current Liabilities | 0.11 | 0.61 | 0.3 | 0.49 | 0.36 |
Long-Term Leases | - | - | - | - | 0.05 |
Pension & Post-Retirement Benefits | 0 | 0.01 | 0 | 0 | 0 |
Total Liabilities | 0.11 | 0.61 | 0.31 | 0.49 | 0.4 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 25.32 | 24.15 | 23.18 | 21.37 | 19.91 |
Retained Earnings | -24.78 | -24.03 | -22.09 | -20.79 | -18.98 |
Comprehensive Income & Other | 0.17 | 0.42 | 0.28 | 0.35 | 0.44 |
Shareholders' Equity | 0.71 | 0.54 | 1.36 | 0.92 | 1.36 |
Total Liabilities & Equity | 0.82 | 1.15 | 1.67 | 1.42 | 1.77 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | - | 0.41 | - | - | 0.07 |
Net Cash (Debt) | 0.47 | -0.31 | 0.98 | 0.4 | 1.1 |
Net Cash Growth | - | - | 144.80% | -63.67% | -67.05% |
Net Cash Per Share | 0.00 | -0.00 | 0.01 | 0.00 | 0.02 |
Filing Date Shares Outstanding | 307.58 | 213.38 | 191.14 | 119.92 | 71.36 |
Total Common Shares Outstanding | 307.58 | 213.38 | 191.14 | 119.92 | 71.36 |
Working Capital | 0.71 | 0.54 | 1.37 | 0.92 | 1.34 |
Book Value Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
Tangible Book Value | 0.71 | 0.54 | 1.36 | 0.92 | 1.36 |
Tangible Book Value Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |